ROCKVILLE, Md.,
Aug. 28, 2019 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq:RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology
Platform, today announced that it will present at the following
September investor conferences:
Citi's 14th Annual Biotech
Conference
Date: Wednesday, September 4,
2019
Location: Four Seasons Hotel, Boston, MA
Gene Therapy Panel: Wednesday,
September 4, 2019 at 10:15 a.m.
ET
Morgan Stanley 17th Annual Global Healthcare
Conference
Date: Tuesday, September 10, 2019
Location: Grand Hyatt, New
York, NY
Fireside Chat: Tuesday, September 10,
2019 at 4:05 p.m. ET
A live webcast of the panel and fireside chat can be accessed in
the Investors section of REGENXBIO's website at www.regenxbio.com.
An archived replay of each webcast will be available on the same
website for approximately 30 days following the presentation. In
addition, REGENXBIO senior management will be holding one-on-one
meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV® Technology Platform, a
proprietary adeno-associated virus (AAV) gene delivery platform,
consists of exclusive rights to more than 100 novel AAV vectors,
including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its
third-party NAV Technology Platform Licensees are applying the NAV
Technology Platform in the development of a broad pipeline of
candidates in multiple therapeutic areas.
CONTACT:
Investors:
Heather
Savelle, 212-600-1902
heather@argotpartners.com
Media:
David Rosen,
212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-upcoming-investor-conferences-300906941.html
SOURCE REGENXBIO Inc.